Cangrelor Tetrasodium

坎格雷洛四钠盐

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameCangrelor Tetrasodium
Drug Alias Name坎格瑞洛cangrelorumcangrelor坎格雷洛坎格瑞洛四钠 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPurinergic receptor P2Y12 antagonists
TargetsPurinergic receptor P2Y12
Therapy Area/IndicationsThrombosisAtherosclerosisMyocardial Infarction +[9] 
Global Approved IndicationsThrombosisMyocardial InfarctionCoronary Thrombosis +[4] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2015/03/23
Country/TerritoryUnited StatesEUMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe Medicines Company
China Registration ClassN/A

Develop Information

Active CompaniesChiesi Usa IncChiesi Farmaceutici SPAJiangsu Aosaikang Pharmaceutical Co Ltd
Inactive CompaniesIcahn School Of Medicine At Mount SinaiThe Medicines Company
Active IndicationsThrombosisMyocardial InfarctionCoronary Thrombosis +[5] 
Inactive IndicationsAtherosclerosisCoronary DiseaseAngina, Stable +[4] 

Other Information

ATC CodeB01AC25
Related LinksWikipediaDrugBankKEGG